Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
-0.23%
$18.67
0% positive prob.
5-Day Prediction
-4.36%
$17.89
0% positive prob.
20-Day Prediction
-1.84%
$18.37
0% positive prob.
SEC 8-K filings with transcript text
Feb 12, 2026 · 100% conf.
1D
-0.23%
$18.67
5D
-4.36%
$17.89
20D
-1.84%
$18.37
bax-202602100000010456false00000104562026-02-102026-02-100000010456bax:CommonStock1.00PerValueMemberexch:XNYS2026-02-102026-02-100000010456bax:CommonStock1.00PerValueMemberexch:XCHI2026-02-102026-02-100000010456bax:GlobalNotes13Due2029Memberexch:XNYS2026-02-102026-02-10
Washington, D.C. 20549
Date of Report (Date of earliest event reported): February 10, 2026 Baxter International Inc. (Exact name of registrant as specified in its charter)
Delaware (State or other jurisdiction of incorporation)
1-444836-0781620 (Commission File Number)(I.R.S. Employer Identification No.)
One Baxter Parkway, Deerfield, Illinois 60015 (Address of principal executive offices)(Zip Code)
(224)948-2000
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $1.00 par valueBAX (NYSE)New York Stock Exchange 1.3% Global Notes due 2029BAX 29New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter): ☐ Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act: ☐
Item 2.02 Results of Operations and Financial Condition. On February 12, 2026, Baxter International Inc. (the Company) issued an earnings press release for the period ended December 31, 2025. The press release, including attachments, is furnished as Exhibit 99.1 to this report. The information in this Item 2.02 of Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.
Item 8.01 Other Events Effective February 11, 2026, the Company's Board of Directors declared a quarterly cash dividend of $0.01 per share of common stock. The dividend is payable on April 1, 2026, to stockholders of record as of February 27, 2026.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Michael R. McDonnell On February 10, 2026, Baxter International Inc. (the “Company”) appointed Michael R. McDonnell to its Board of Directors (the “Board”), effective February 13, 2026. Mr. McDonnell has also been appointed to serve as a member of the Audit Committee. Michael McDonnell served as the Executive Vice President and Chief Financial Officer of Biogen Inc. from August 2020 through February 2025. He also served as Executive Vice President and Chief Financial Officer of IQVIA Holdings Inc. (f/k/a Quintiles IMS) from December 2015 through July 2020. Prior to that, Mr. McDonnell served as the Executive Vice President and Chief Financial Officer of Intelsat S.A. from November 2008 to December 2015, as Executive Vice President, Chief Financial Officer of MCG Capital Corporation from September 2004 until October 2008 and also as MCG Capital Corporation’s Chief Operating Officer from August 2006 until October 2008. Before joining MCG Capital Corporation, Mr. McDonnell served as Executive Vice President and Chief Financial Officer for Echo Star Communications Corporation (d/b/a DISH Network Corporation) from July 2004 until August 2004 and as its Senior Vice President and Chief Financial Officer from August 2000 to July 2004. Mr. McDonnell spent 14 years at PricewaterhouseCoopers LLP, including four years as a partner. Mr. McDonnell also serves on the board of directors of Merit Medical Systems, Inc. Mr. McDonnell will be compensated f
Oct 30, 2025
bax-202510300000010456false00000104562025-10-302025-10-300000010456bax:CommonStock1.00PerValueMemberexch:XCHI2025-10-302025-10-300000010456bax:CommonStock1.00PerValueMemberexch:XNYS2025-10-302025-10-300000010456bax:GlobalNotes13Due2029Memberexch:XNYS2025-10-302025-10-30
Washington, D.C. 20549
Date of Report (Date of earliest event reported): October 30, 2025 Baxter International Inc. (Exact name of registrant as specified in its charter)
Delaware (State or other jurisdiction of incorporation)
1-444836-0781620 (Commission File Number)(I.R.S. Employer Identification No.)
One Baxter Parkway, Deerfield, Illinois 60015 (Address of principal executive offices)(Zip Code)
(224)948-2000
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $1.00 par valueBAX (NYSE)New York Stock Exchange 1.3% Global Notes due 2029BAX 29New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter): ☐ Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act: ☐
Item 2.02 Results of Operations and Financial Condition. On October 30, 2025, Baxter International Inc. (the Company) issued an earnings press release for the period ended September 30, 2025. The press release, including attachments, is furnished as Exhibit 99.1 to this report.
The information in this Item 2.02 of Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits. (d)Exhibits.
Exhibit NumberDescription
99.1Press Release Dated October 30, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 30, 2025
By:/s/ Joel T. Grade Name:Joel T. Grade Title:Executive Vice President and Chief Financial Officer
Jul 31, 2025
bax-202507310000010456false00000104562025-07-312025-07-310000010456exch:XCHIbax:CommonStock1.00PerValueMember2025-07-312025-07-310000010456exch:XNYSbax:CommonStock1.00PerValueMember2025-07-312025-07-310000010456exch:XNYSbax:GlobalNotes13Due2029Member2025-07-312025-07-31
Washington, D.C. 20549
Date of Report (Date of earliest event reported): July 31, 2025 Baxter International Inc. (Exact name of registrant as specified in its charter)
Delaware (State or other jurisdiction of incorporation)
1-444836-0781620 (Commission File Number)(I.R.S. Employer Identification No.)
One Baxter Parkway, Deerfield, Illinois 60015 (Address of principal executive offices)(Zip Code)
(224)948-2000
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $1.00 par valueBAX (NYSE)New York Stock Exchange 1.3% Global Notes due 2029BAX 29New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter): ☐ Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act: ☐
Item 2.02 Results of Operations and Financial Condition. On July 31, 2025, Baxter International Inc. (the Company) issued an earnings press release for the period ended June 30, 2025. The press release, including attachments, is furnished as Exhibit 99.1 to this report.
The information in this Item 2.02 of Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits. (d)Exhibits.
Exhibit NumberDescription
99.1Press Release Dated July 31, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 31, 2025
By:/s/ Joel T. Grade Name:Joel T. Grade Title:Executive Vice President and Chief Financial Officer
This page provides Baxter International Inc. (BAX) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on BAX's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.